Yahoo Web Search

Search results

1. • Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of...

     Morningstar· 1 day ago

     Gilead and Arcus Announce EtrumadenantPlus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer – In Cohort B of the ARC-9 mCRC Study, Etrumadenant ...

2. • Small Business - Cordele Dispatch | Cordele Dispatch

     Cordele Dispatch· 24 hours ago

     -- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles

3. • 

     Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca By...

     Investing.com· 4 days ago

     In their first quarter 2024 earnings call, Cellectis, a biopharmaceutical company, presented a...

4. • 

     Cell therapy reckoning: Pivot to autoimmune leaves unmet need in oncology

     FierceBiotech· 4 days ago

     This story is part 2 in a four-part series about cell therapy created by the Fierce Biotech team....

5. • Cellectis Reports Financial Results for First Quarter 2024

     Morningstar· 6 days ago

     • Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 • Conference call and webcast scheduled for tomorrow, May 29, 2024